Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pharmacokinetics of apatinib in healthy male Caucasian, Japanese and Chinese subjects.

Trial Profile

Pharmacokinetics of apatinib in healthy male Caucasian, Japanese and Chinese subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Adenoid cystic carcinoma; Breast cancer; Cholangiocarcinoma; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Liver cancer; Lung cancer; Malignant melanoma; Non-small cell lung cancer; Oesophageal cancer; Osteosarcoma; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Soft tissue sarcoma; Solid tumours; Uterine cancer
  • Focus Pharmacokinetics
  • Most Recent Events

    • 28 Sep 2017 New trial record
    • 01 Sep 2017 Results assessing Pharmacokinetics of apatinib in healthy Caucasian, Japanese and Chinese subjects following a single-dose administration, were published in the Clinical Pharmacology in Drug Development Conference: 2017 Annual Meeting of the American College of Clinical Pharmacology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top